Renaissance Technologies LLC decreased its stake in Utah Medical Products, Inc. (NASDAQ:UTMD - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,510 shares of the medical instruments supplier's stock after selling 9,104 shares during the quarter. Renaissance Technologies LLC owned approximately 6.53% of Utah Medical Products worth $13,616,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in shares of Utah Medical Products by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,411 shares of the medical instruments supplier's stock worth $4,644,000 after purchasing an additional 6,645 shares in the last quarter. State Street Corp increased its stake in Utah Medical Products by 0.9% in the third quarter. State Street Corp now owns 80,856 shares of the medical instruments supplier's stock valued at $5,434,000 after purchasing an additional 694 shares in the last quarter. Barclays PLC grew its holdings in shares of Utah Medical Products by 214.1% in the 3rd quarter. Barclays PLC now owns 4,574 shares of the medical instruments supplier's stock valued at $306,000 after buying an additional 3,118 shares during the period. Sanctuary Advisors LLC increased its position in shares of Utah Medical Products by 16.1% in the 4th quarter. Sanctuary Advisors LLC now owns 6,961 shares of the medical instruments supplier's stock valued at $426,000 after buying an additional 963 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Utah Medical Products by 102.7% during the third quarter. BNP Paribas Financial Markets now owns 1,117 shares of the medical instruments supplier's stock worth $75,000 after acquiring an additional 566 shares in the last quarter. 69.60% of the stock is currently owned by institutional investors and hedge funds.
Utah Medical Products Stock Performance
UTMD stock traded down $0.10 during mid-day trading on Friday, hitting $52.30. 10,925 shares of the company were exchanged, compared to its average volume of 20,256. The firm has a market cap of $171.65 million, a P/E ratio of 13.24 and a beta of 0.17. Utah Medical Products, Inc. has a 1-year low of $52.27 and a 1-year high of $77.33. The firm's 50 day simple moving average is $57.18 and its 200 day simple moving average is $61.38.
Utah Medical Products (NASDAQ:UTMD - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter. Utah Medical Products had a return on equity of 11.07% and a net margin of 33.92%.
Utah Medical Products Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 3rd. Stockholders of record on Friday, March 14th were given a $0.305 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.22 dividend on an annualized basis and a dividend yield of 2.33%. Utah Medical Products's payout ratio is 30.89%.
About Utah Medical Products
(
Free Report)
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Featured Stories
Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
